Results: Atotal of 83 ovarian cancer patients treated with PARPi were identified, and of these, 61 (73.5%) were treated with PARPi in the maintenance setting. Among the patients treated with PARPi maintenance, 22 (36.1%) remain on tre...
Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and is initially very responsive to platinum-based chemotherapy. However, the majority of patients relapse following initial surgery and chemotherapy, highlighting the urgent need to develop new therapeutic strategies. ...
This is one of the most effective mode of ovarian cancer treatment in India. Women suffering at any stage, be it early or advanced, can be treated by cancer healer therapy with great success. Treatment may be used alone or in conjunction with other treatments such as radiation therapy, ...
296 Ovarian cancer–new insights into systemic therapyThe introduction of paclitaxel (Taxol) to the treatment of ovarian cancer has encouraged discussion about its role in initial treatment programs. The Gynecologic Oncology Group showed in FIGO stage III and IV, sub-optimally debulked disease that ...
(1.2%) patients treated with placebo. The duration of therapy with ZEJULA in patients who developed secondary MDS/cancer therapy-related AML varied from 3.7 months to 2.5 years. All patients who developed secondary MDS/cancer therapy-related AML had received previous chemotherapy with platinum agents...
home/clinical-consult/ovarian-cancer-frontline-therapy Dr. Rebecca Previs from the Duke Cancer Center reviews frontline therapy options for patients with advanced ovarian cancer. EP. 1:Initial Therapy Options for Advanced Ovarian Cancer Rebecca Previs, MD ...
In a culture dish, the researchers had treated two sets of cancer cells with two different epigenetic therapy drugs: one with 5-azacytidine (AZA), aDNA methyltransferaseinhibitor that removes methyl groups from DNA, and the other withhistone deacetylaseinhibitors (HDACi), an epigenetic enzyme that...
"The main goal in ovarian cancer is to avoid relapse after first-line therapy because otherwise the probability of cure is quite low. The combination of bevacizumab and olaparib as maintenance therapy should become a new standard of care for patients with advanced ovarian cancer. The PAOLA-1/ENG...
Ovarian cancer is an abnormal cell growth (tumour) arising in the ovary. The majority of ovarian cancers are epithelial and develop in women over 50. Screening is highly recommended in women with a family history of ovarian cancer.Latest Research and Reviews A targetable OSGIN1 − AMPK...
claiming more lives than any other tumour of the reproductive system. One of the major challenges in treating women with ovarian cancer is that diagnosis is usually made when the disease has spread beyond the ovary. Although surgery is still considered the first-line intervention, the majority of...